ECSP19075134A - Sistemas de administración de liberación sostenida que comprenden ligantes que no dejan huellas - Google Patents

Sistemas de administración de liberación sostenida que comprenden ligantes que no dejan huellas

Info

Publication number
ECSP19075134A
ECSP19075134A ECSENADI201975134A ECDI201975134A ECSP19075134A EC SP19075134 A ECSP19075134 A EC SP19075134A EC SENADI201975134 A ECSENADI201975134 A EC SENADI201975134A EC DI201975134 A ECDI201975134 A EC DI201975134A EC SP19075134 A ECSP19075134 A EC SP19075134A
Authority
EC
Ecuador
Prior art keywords
sustained release
trackling
binders
drug delivery
systems including
Prior art date
Application number
ECSENADI201975134A
Other languages
English (en)
Inventor
Edward Charles Hall
Myriam April
Cameron Chuck-Munn Lee
Cornelia Jutta Forster
Tanzina Fazal
Christopher M Adams
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62116508&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP19075134(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP19075134A publication Critical patent/ECSP19075134A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describen sistemas de administración de fármacos para administrar agentes biológicamente activos que comprenden aminas primarias o secundarias, o un átomo de nitrógeno anular de un anillo de azaheteroarilo, sales farmacéuticamente aceptables de los mismos, reactivos de administración de fármacos relacionados con los mismos, composiciones farmacéuticas que comprenden los sistemas de administración de fármacos y el uso de los sistemas de administración de fármacos como terapias de liberación sostenida.
ECSENADI201975134A 2017-04-20 2019-10-18 Sistemas de administración de liberación sostenida que comprenden ligantes que no dejan huellas ECSP19075134A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762487888P 2017-04-20 2017-04-20

Publications (1)

Publication Number Publication Date
ECSP19075134A true ECSP19075134A (es) 2019-10-31

Family

ID=62116508

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201975134A ECSP19075134A (es) 2017-04-20 2019-10-18 Sistemas de administración de liberación sostenida que comprenden ligantes que no dejan huellas

Country Status (26)

Country Link
US (3) US10751417B2 (es)
EP (1) EP3612233A1 (es)
JP (1) JP7323453B2 (es)
KR (1) KR20190137888A (es)
CN (1) CN110603060A (es)
AR (1) AR111481A1 (es)
AU (1) AU2018255933B2 (es)
BR (1) BR112019021810A2 (es)
CA (1) CA3057590A1 (es)
CL (1) CL2019002969A1 (es)
CO (1) CO2019011577A2 (es)
CR (1) CR20190479A (es)
CU (1) CU20190082A7 (es)
DO (1) DOP2019000268A (es)
EA (2) EA202192099A3 (es)
EC (1) ECSP19075134A (es)
IL (1) IL269991B2 (es)
JO (1) JOP20190245A1 (es)
MA (1) MA50260A (es)
MX (1) MX2019012447A (es)
PE (2) PE20191837A1 (es)
PH (1) PH12019502325A1 (es)
SG (1) SG11201908740VA (es)
TW (1) TW201842935A (es)
UY (1) UY37686A (es)
WO (1) WO2018193408A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6833811B2 (ja) 2015-08-03 2021-02-24 プレジデント アンド フェローズ オブ ハーバード カレッジ 荷電イオンチャネル遮断薬及び使用方法
MX2019002835A (es) 2016-09-13 2019-09-04 Allergan Inc Composiciones no proteínicas de toxina clostridial.
MX2019008449A (es) 2017-02-08 2019-09-09 Bristol Myers Squibb Co Polipetidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos.
JOP20190245A1 (ar) * 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
AR116566A1 (es) * 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
US10780083B1 (en) 2019-03-11 2020-09-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10828287B2 (en) 2019-03-11 2020-11-10 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
CA3129089A1 (en) 2019-03-11 2020-09-17 Bridget Mccarthy Cole Ester substituted ion channel blockers and methods for use
AU2020237474A1 (en) 2019-03-11 2021-09-30 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US11377422B2 (en) 2019-03-11 2022-07-05 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
WO2020254611A1 (en) * 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 conjugates
WO2020254617A1 (en) * 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pk properties
WO2020254607A1 (en) * 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pd properties
US11795320B2 (en) * 2019-09-20 2023-10-24 Bausch + Lomb Ireland Limited Grafted polymer and use thereof
US10933055B1 (en) 2019-11-06 2021-03-02 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
KR20220123381A (ko) 2019-11-06 2022-09-06 녹시온 테라퓨틱스 인코포레이티드 하전된 이온 채널 차단제 및 사용 방법
CN111110829A (zh) * 2019-12-24 2020-05-08 浙江大学 一种纳米防御素凝胶支架及其制备方法和应用
EP4118070A4 (en) 2020-03-11 2024-04-10 Nocion Therapeutics, Inc. CHARGED ION CHANNEL BLOCKERS AND METHODS OF USE
CN111285736A (zh) * 2020-04-09 2020-06-16 郑州先利达化工有限公司 含亚磷酸钾、矿源黄腐酸钾、聚谷氨酸的药肥组合物
CN114129780B (zh) * 2020-09-03 2022-06-28 天津大学 一种光控释放一氧化氮的复合水凝胶的制备及应用
WO2023034299A1 (en) * 2021-08-31 2023-03-09 The Research Foundation For The State University Of New York Shear-thinning hydrogels and uses thereof
US20240075001A1 (en) * 2022-05-24 2024-03-07 Darren Rubin Methods to reduce hemorrhage and mortality on the battlefield and applications for trauma patients
CN115074402B (zh) * 2022-07-20 2022-11-18 点滴(南京)生物科技有限公司 一种采用酶法合成的γ-聚谷氨酸钠交联水凝胶及其合成方法
WO2024073588A1 (en) * 2022-09-28 2024-04-04 Board Of Regents, The University Of Texas System Respiratory dry powder delivery
CN115947956B (zh) * 2022-10-09 2024-03-19 西北农林科技大学 一种基于细菌纤维素纳米晶的皮克林纳米乳液及应用
US12064467B2 (en) 2022-10-28 2024-08-20 Transdermal Biotechnology, Inc. Systems and methods for delivery of humanin or other peptides
WO2024146902A1 (en) 2023-01-05 2024-07-11 Ascendis Pharma A/S Methods of producing hydrogel microspheres
WO2024146920A1 (en) 2023-01-05 2024-07-11 Ascendis Pharma Ophthalmology Division A/S Drug conjugates for the treatment of ocular disorders
CN116253809A (zh) * 2023-04-19 2023-06-13 广州润虹医药科技股份有限公司 一种去除壳聚糖中内毒素的方法

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3737523A1 (de) 1987-11-05 1989-05-18 Bayer Ag Verwendung von substituierten hydroxypiperidinen als antivirale mittel
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5658592A (en) 1994-05-13 1997-08-19 Kuraray Co., Ltd. Medical crosslinked polymer gel of carboxylic polysaccharide and diaminoalkane
WO1998009987A1 (en) 1996-09-06 1998-03-12 Biochem Pharma, Inc. Lactam inhibitors of thrombin
NZ500078A (en) 1997-04-07 2001-10-26 Genentech Inc Humanized anti-VEGF antibodies and their use in inhibiting VEGF-induced angiogenesis in mammals
AU6419899A (en) 1998-10-09 2000-05-01 Regents Of The University Of Michigan, The Hydrogels and water soluble polymeric carriers for drug delivery
US7169777B2 (en) 2001-01-23 2007-01-30 Eli Lilly And Company Melanocortin receptor agonists
WO2005028502A1 (en) 2003-09-18 2005-03-31 Vertex Pharmaceuticals, Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US8377917B2 (en) 2004-03-23 2013-02-19 Complex Biosystems Gmbh Polymeric prodrug with a self-immolative linker
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
CA2614049C (en) 2005-07-06 2014-12-02 Molly S. Shoichet Method of biomolecule immobilization on polymers using click-type chemistry
US20070060658A1 (en) 2005-08-31 2007-03-15 Diaz David D Stabilization of organogels and hydrogels by azide-alkyne [3+2] cycloaddition
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
CA2653781A1 (en) 2006-06-09 2007-12-13 Novartis Ag Stabilized insulin-like growth factor polypeptides
ITMI20061726A1 (it) * 2006-09-11 2008-03-12 Fidia Farmaceutici Derivati crosslinkati a base di acido ialuronico reticolato via click chemistry
MX2009008518A (es) 2007-02-09 2009-08-20 Irm Llc Compuestos y composiciones como inhibidores de la proteasa activadora de canal.
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
WO2008119741A2 (en) 2007-03-29 2008-10-09 Novartis Ag 3-imidazolyl-indoles for the treatment of proliferative diseases
CA2689909C (en) 2007-06-08 2016-04-05 Ascendis Pharma As Long-acting polymeric prodrugs of exendin
US20110006980A1 (en) 2008-01-31 2011-01-13 Appside Co., Ltd. Data input device, data input method, data input program, and recording medium containing the program
RU2010136023A (ru) 2008-02-01 2012-03-10 Асцендис Фарма Ас (Dk) Пролекарство, содержащее саморасщепляемый линкер
EP3216803B1 (en) 2008-06-25 2020-03-11 Novartis Ag Stable and soluble antibodies inhibiting vegf
CN102272120B (zh) 2008-11-07 2013-12-25 H.隆德贝克有限公司 生物活性酰胺
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
CA2753179A1 (en) 2009-02-21 2010-08-26 Sofradim Production Crosslinked fibers and method of making same by extrusion
WO2010099818A1 (en) 2009-03-03 2010-09-10 Ao Technology Ag Thermoreversible polysaccharide hydrogel
WO2010102663A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Piperazine derivatives for use in therapy
IN2012DN00352A (es) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
TW201113280A (en) 2009-07-03 2011-04-16 Nensius Res As Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the CNS
WO2011012723A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Injectable sustained release compositions comprising a pramipexole prodrug
RU2556340C2 (ru) 2009-07-31 2015-07-10 Санофи-Авентис Дойчланд Гмбх Композиция инсулина длительного действия
HUE052816T2 (hu) * 2009-07-31 2021-05-28 Ascendis Pharma As Biológiailag lebontható polietilénglikol bázisú vízoldható hidrogélek
US20120191039A1 (en) 2009-07-31 2012-07-26 Ascendis Pharma A/S Carrier linked pramipexole prodrugs
US9173953B2 (en) 2009-07-31 2015-11-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
SG178193A1 (en) 2009-07-31 2012-03-29 Sanofi Aventis Deutschland Prodrugs comprising an insulin linker conjugate
WO2011042453A1 (en) 2009-10-06 2011-04-14 Ascendis Pharma As Subcutaneous paliperidone composition
US20130053405A1 (en) 2009-10-06 2013-02-28 Ulrich Hersel Carrier linked paliperidone prodrugs
US8986609B2 (en) 2009-10-29 2015-03-24 Ascendis Pharma A/S Sterilization of biodegradable hydrogels
US9561285B2 (en) 2010-01-22 2017-02-07 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
WO2011089216A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
EP2525829A1 (en) 2010-01-22 2012-11-28 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
CN103153927B (zh) 2010-04-27 2017-02-15 西纳福克斯股份有限公司 稠合的环辛炔化合物及其在无金属点击反应中的应用
WO2011140392A1 (en) 2010-05-05 2011-11-10 Prolynx Llc Controlled drug release from solid supports
CN103201267B (zh) 2010-07-29 2016-08-17 里格尔药品股份有限公司 Ampk-激活性杂环化合物以及其使用方法
EP2678326B1 (en) 2011-02-25 2017-08-02 University of Massachusetts Medical School Monomers and polymers for functional polycarbonates and poly (ester-carbonates) and peg-co-polycarbonate hydrogels
CZ304072B6 (cs) 2011-04-26 2013-09-25 Contipro Biotech S.R.O. Amfoterní materiál na bázi sítované kyseliny hyaluronové, zpusob jeho prípravy, materiály obsahující aktivní cinidla uzavrené v síti hyaluronanu, zpusob jejich prípravy a jejich pouzití
EP2716662A4 (en) 2011-05-31 2014-11-19 Univ Tokyo HYDROGEL AND METHOD FOR ITS MANUFACTURE
WO2012173952A1 (en) 2011-06-13 2012-12-20 Emory University Piperazine derivatives, compositions, and uses related thereto
WO2013024051A1 (en) 2011-08-12 2013-02-21 Ascendis Pharma A/S Sustained release composition of prostacyclin
JP6158185B2 (ja) 2011-09-07 2017-07-05 プロリンクス エルエルシー 生分解性架橋を有するヒドロゲル
EP2753607B1 (en) 2011-09-09 2016-04-13 Berry And Associates, Inc. Bicyclo[6.1.0]non-4-yne reagents for chemical modification of oligonucleotides
KR20140103099A (ko) 2011-10-12 2014-08-25 아센디스 파마 옵탈몰로지 디비젼 에이/에스 안구 병태의 예방 및 치료
JP2013116858A (ja) 2011-12-01 2013-06-13 Dainippon Sumitomo Pharma Co Ltd Ｂｄｎｆ様低分子化合物を含有する治療薬
WO2013078564A2 (en) 2011-12-01 2013-06-06 Angiochem Inc. Targeted lysosomal enzyme compounds
JP2015500800A (ja) 2011-12-01 2015-01-08 アンジオケム インコーポレーテッド 標的化イズロン酸−２−スルファターゼ化合物
CA2873793C (en) 2012-05-18 2022-02-22 Medical Research Council Methods of incorporating an amino acid comprising a bcn group into a polypeptide using an orthogonal codon encoding it and an orthorgonal pylrs synthase
JP6271566B2 (ja) 2012-10-11 2018-01-31 アセンディス ファーマ エー／エス ヒドロゲルプロドラッグ
SG11201501920PA (en) 2012-10-11 2015-04-29 Ascendis Pharma As Diagnosis, prevention and treatment of diseases of the joint
RU2673881C2 (ru) * 2012-10-11 2018-12-03 Асцендис Фарма Офтальмолоджи Дивижн А/С Vegf-нейтрализующие пролекарства для лечения офтальмологических заболеваний
US20150267196A1 (en) 2012-10-12 2015-09-24 Case Western Reserve University Biodegradable hydrogel for polynucleotide delivery
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US20150352246A1 (en) 2013-01-22 2015-12-10 Prolynx Llc Sealants having controlled degration
MX2015010146A (es) * 2013-02-08 2016-05-31 Novartis Ag Sitios especificos para modificar anticuerpos para hacer inmunoconjugados.
EP2968590B1 (en) 2013-03-15 2018-09-05 Novartis AG Antibody drug conjugates
EP2988783A1 (en) 2013-04-22 2016-03-02 Ascendis Pharma A/S Hydrogel-linked prodrugs releasing modified drugs
WO2014173762A1 (en) 2013-04-22 2014-10-30 Ascendis Pharma A/S Modified hydrogels
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
CN104292454B (zh) * 2013-07-17 2017-12-01 北京键凯科技股份有限公司 聚乙二醇‑环辛炔衍生物
US9683018B2 (en) 2013-07-25 2017-06-20 Novartis Ag Disulfide cyclic polypeptides for the treatment of heart failure
WO2015013168A1 (en) 2013-07-25 2015-01-29 Novartis Ag Cyclic polypeptides for the treatment of heart failure
EP3024846A1 (en) 2013-07-25 2016-06-01 Novartis AG Cyclic apelin derivatives for the treatment of heart failure
JP2016172783A (ja) 2013-08-08 2016-09-29 生化学工業株式会社 組織膨隆材
CA2924661A1 (en) 2013-10-08 2015-04-16 Ascendis Pharma Osteoarthritis Division A/S Hydrogel-linked il-1ra prodrug
JP2016534064A (ja) 2013-10-22 2016-11-04 プロリンクス エルエルシー ソマトスタチン及びその類似体のコンジュゲート
AU2014345511A1 (en) 2013-11-11 2016-05-12 Ascendis Pharma A/S Relaxin prodrugs
EP3110450B1 (en) 2014-02-26 2023-06-07 University of Massachusetts Medical School Degradable hydrogel with predictable tuning of properties, and compositions and methods thereof
EP3193941B1 (en) 2014-08-06 2024-05-22 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
WO2016025752A1 (en) 2014-08-14 2016-02-18 Prolynx Llc Reagents for thiol conjugation and conjugates formed therefrom
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
WO2016110577A1 (en) 2015-01-09 2016-07-14 Ascendis Pharma A/S Cnp prodrugs
US20180117171A1 (en) * 2015-04-01 2018-05-03 President And Fellows Of Harvard College Immunoconjugates for programming or reprogramming of cells
WO2016196124A2 (en) 2015-05-29 2016-12-08 Ascendis Pharma Inc. Prodrugs comprising a pyroglutamate linker
BR112018010205A2 (pt) 2015-11-20 2018-11-21 Cristal Delivery B V nanopartículas com direcionamento ativo
US20200164083A1 (en) 2016-03-16 2020-05-28 Prolynx Llc Extended release conjugates of exenatide analogs
US11896671B2 (en) 2016-07-13 2024-02-13 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
JOP20190245A1 (ar) * 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط

Also Published As

Publication number Publication date
PH12019502325A1 (en) 2020-07-06
JP2020517623A (ja) 2020-06-18
CN110603060A (zh) 2019-12-20
BR112019021810A2 (pt) 2020-05-26
CA3057590A1 (en) 2018-10-25
US20200376129A1 (en) 2020-12-03
SG11201908740VA (en) 2019-11-28
CU20190082A7 (es) 2020-10-20
EA201992484A1 (ru) 2020-02-25
IL269991B1 (en) 2023-03-01
JP7323453B2 (ja) 2023-08-08
CL2019002969A1 (es) 2020-02-07
EA202192099A3 (ru) 2022-02-28
MX2019012447A (es) 2020-01-13
AU2018255933A1 (en) 2019-10-17
DOP2019000268A (es) 2020-02-16
JOP20190245A1 (ar) 2019-10-15
RU2019136872A3 (es) 2021-08-31
WO2018193408A1 (en) 2018-10-25
US20230201353A1 (en) 2023-06-29
EP3612233A1 (en) 2020-02-26
US10751417B2 (en) 2020-08-25
RU2019136872A (ru) 2021-05-21
US20180303945A1 (en) 2018-10-25
UY37686A (es) 2018-11-30
AR111481A1 (es) 2019-07-17
CO2019011577A2 (es) 2019-10-31
KR20190137888A (ko) 2019-12-11
PE20191837A1 (es) 2019-12-30
AU2018255933B2 (en) 2021-09-30
CR20190479A (es) 2019-11-20
IL269991A (es) 2019-12-31
IL269991B2 (en) 2023-07-01
TW201842935A (zh) 2018-12-16
EA202192099A2 (ru) 2021-11-30
PE20211281A1 (es) 2021-07-19
MA50260A (fr) 2020-02-26

Similar Documents

Publication Publication Date Title
ECSP19075134A (es) Sistemas de administración de liberación sostenida que comprenden ligantes que no dejan huellas
DOP2021000053A (es) Administración sostenida de polipéptidos similares a la angiopoyetina 3
ECSP22047876A (es) Derivados de pirazolilo ?tiles como agentes anticancer?genos
BR112015018087A8 (pt) composto, composição farmacêutica e uso
MX2020007625A (es) Inhibidor mtor, composicion farmaceutica y su uso.
CL2020003174S1 (es) Dispositivo para administración de dosis.
CO2019000643A2 (es) Formulaciones gastrorretentivas orales y usos de las mismas
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
BR112019003811A2 (pt) composição farmacêutica, método para aumentar os níveis plasmáticos de antagonista do receptor de nmda em um sujeito que precisa do mesmo, método para tratar uma doença ou transtorno em um sujeito que precisa do mesmo e uso da composição
UY36003A (es) Derivados de amida, procesos de preparación y composiciones, útiles en afecciones asociadas con el receptor sub-tipo 1 de orexina.
DOP2019000070A (es) Compuestos de aza–indazol para usar en lesiones de tendones y/o ligamentos
BR112017019653A2 (pt) derivados heteroaril bicíclicos fundidos tendo atividade como inibidores de phd
BR112018072113A2 (pt) excipiente à base de proteínas para ingredientes farmacêuticos ativos
CR20180184A (es) Compuestos heteroarilo y su uso como fármacos terapéuticos
UY37412A (es) Compuestos de indazol para uso en lesiones de tendones y/o ligamentos
CO2018007610A2 (es) Derivados de indano y su uso en terapias
NI202000095A (es) Métodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropión
CO2019011299A2 (es) Formulaciones con mayor estabilidad y biodisponibilidad para administración de (e)-2,6-dialcoxiestiril bencilsulfonas sustituidas en 4
UY36958A (es) Compuestos para administración intracelular
CO2020006552A2 (es) Composiciones farmaceuticas que comprenden safinamida
AR117298A1 (es) Aglutinante de péptido
HK1257466A2 (zh) 皮膚病的藥物製劑